kevintx

Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership

Lorcaserin is looking strong here. Other obesity drug candidates are having a hard time e.g. Merck's. Evolving standards for psychological side effects are raising the bar. Existing drug options are lacking. Increasing prevalence of obesity has been a stable long term trend.
ARNA is also trading rather cheaply here, has a sizable cash reserve, and has other drugs in the pipeline. I'll stick with it.